Houston-based ROGII has acquired a new software to integrate into its platform. Photo via ROGII.com

An advanced geosteering, geoscience, and drilling software solutions company based in Houston has announced the acquisition of of a software platform.

ROGII plans to acquire TerraSLS's TLog Mudlog Editor software, which is used to generate vertical, and horizontal striplogs for use by geologists. The acquisition “will significantly enhance ROGII's product offerings by providing operators and clients with unprecedented real-time connectivity to mudlogging data,” according to ROGII. Mudlogging is a process that involves examining the cuttings of rock brought to the surface by the drilling.

“Our acquisition of TLog marks another step forward in our mission to deliver the most advanced, real-time data solutions to the oil and gas industry,” CEO of ROGII Igor B. Uvarov says in a news release. “The integration of TLog’s capabilities into our Solo Cloud platform will revolutionize the way operators and mudlogging service companies interact, making mudlogging a truly real-time process and driving greater efficiency and collaboration.”

One way it works is that ROGII will integrate TLog into its Solo Cloud platform, which will advance mudlogging data. This gathers it all into a real-time data exchange between mudlogging service companies and its operators.

The integration will allow operators to monitor mudlogging activities in real-time, which means a possible faster and more informed decision-making processes. The user will get immediate access to data, which can help enhance collaboration and improve efficiency. In addition, the mudlogging data will be safely stored on Solo Cloud for future analysis and data integration, which assists with maintaining integrity of the data.

“We look forward to investing in further development of TLog, increasing user-friendliness, expanding adoption worldwide, and making it the industry standard, being used by all mudlogging service companies,” Uvarov adds.

------

This article originally ran on EnergyCapital.

The Karimi siblings have created a way to synthetically convert CO2 into glucose, and they are targeting the energy and aerospace industries for their technology. Courtesy of Cemvita Factory

Houston company is solving the energy and space industries' carbon dioxide problems with synthetic photosynthesis

See ya, CO2

Houston-based Cemvita Factory is unlike most startups. Before even knowing what industry they were going to affect, Moji Karimi and his sister, Tara, established their company, which uses synthetic photosynthesis — the process of turning carbon dioxide into glucose for plants.

"In some ways, this company started with the solution, rather than the problem," Moji Karimi, co-founder of Cemvita, says. "Then we said, 'if we could replicate photosynthesis, what problems can we solve?'"

Once the technology was set in place, Karimi, who has a background in oil and gas drilling, says he identified the energy industry in need of something like this. He says he saw an increased pressure on large energy companies to adapt sustainable ways to get rid of the CO2 that is produced as a result of drilling.

More and more companies are investing in a process called carbon dioxide capturing — but it's expensive and not yet cost efficient for energy companies to commit to. But that's changing. Karimi says the process that once cost $600 per ton of CO2 now can be found as cheap as $30.

With his sister's technology, Karimi says they can take that captured carbon dioxide and turn it into other chemicals too. Each oil and gas company client can specify what they want to turn it into and, for less than $100,000, Cemvita will run a pilot program for them. Cemvita sells the exclusive rights to the technology, but still maintains its IP.

"We go to these companies and say, 'What do you want to convert CO2 into?,'" Karimi says. "Then, we do a quick pilot in six months in our lab, and we show them the metrics. They decide if they want to scale it up."

What seemed like another obvious industry for this process was aerospace. Many companies involved in aerospace exploration have Mars on the mind, and the planet's atmosphere is over 95 percent carbon dioxide. Plus, Cemvita can provide a more sustainable way to dispose of CO2 onboard spacecrafts. The current practice is essentially just discarding it by filtering it off the spaceship.

Putting a system in place
Cemvita was founded in August of 2017 and used 2018 to really establish itself. The company took second place at Dubai's Mohammed bin Rashid Space Centre Innovation Challenge and completed the accelerator program at Capital Factory.

Realizing the process is new and without the backing of an educational institution, Karimi says he and his sister needed a way to answer any questions and concerns, so Tara wrote a book. "Molecular Mechanisms of Autonomy in Biological Systems" is published by Springer.

Karimi also lead a talk at Tudor Pickering Holt's Energy Disruptor conference. His discussion, "From Mars to Midland," garnered a lot of interest from energy professionals.

The future is now
Karimi says 2019 is all about execution. He never thought he and his sister would overlap their industries, but now there's more of a need of interdisciplinary collaboration than ever before.

"There are a lot of opportunities bringing a proven science or technology from one industry into another to solve problems," he says.

The company has growth plans this year. The team has bootstrapped everything financially so far, but is looking for its first funding round in the middle of 2019. And, as far as the Karimi siblings are concerned, they are in the exact right place to grow.

"We're in Houston, and we have a technology that is from biotech and have applications in the space industry and the energy industry," Karimi says. "There would not have been any better place for us in the country than Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”